Persistent Fetal Circulation Syndrome
A syndrome of persistent PULMONARY HYPERTENSION in the newborn infant (INFANT, NEWBORN) without demonstrable HEART DISEASES. This neonatal condition can be caused by severe pulmonary vasoconstriction (reactive type), hypertrophy of pulmonary arterial muscle (hypertrophic type), or abnormally developed pulmonary arterioles (hypoplastic type). The newborn patient exhibits CYANOSIS and ACIDOSIS due to the persistence of fetal circulatory pattern of right-to-left shunting of blood through a patent ductus arteriosus (DUCTUS ARTERIOSUS, PATENT) and at times a patent foramen ovale (FORAMEN OVALE, PATENT).
Drugs by status
Approved for this indication (1)
Phase 4 trials (5)
Phase 2 trials (2)
Other trials (2)
Organizations
Organization Involved with Phase 4 Indications (5)
Organization Involved with Phase 3 Indications (34)
- Actelion
- Pfizer
- Hamad Medical Corporation
- National Center for Research Resources (NCRR)
- Baylor University
- Brown University
- Case Western Reserve University
- Cornell University
- Emory University
- University of Washington
- Indiana University
- McGill University
- McMaster University
- Stanford University
- University of Miami
- University of New Mexico
- University of Ottawa
- University of Saskatchewan
- University of Sydney
- University of Tennessee
- Wayne State University
- Yale University
- University of British Columbia
- University of Calgary
- University of California, San Diego
- University of Cincinnati
- University of Texas at Houston
- University of Wisconsin
- George Washington University
- Canadian Institutes of Health Research (CIHR)
- +4 more
Organization Involved with Phase 2 Indications (4)
Organization Involved with Phase 1 Indications (3)
Organization Involved with Other Experimental Indications (4)